Knopp News Archive
Dexpramipexole
Dexpramipexole Targets Eosinophilic Inflammation
Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma
Knopp Biosciences and University of Leicester Announce Update on Planned Phase 2 Clinical Trial of Oral Dexpramipexole in Severe Eosinophilic Asthma
American Society of Hematology: “Dexpramipexole: a new antieosinophil drug?”
Developing Dexpramipexole for the Treatment of Eosinophilic Disorders
Dexpramipexole Responsiveness is Increased in Eosinophilic Subjects
Knopp Biosciences to Present Clinical Data for Dexpramipexole at 11th Biennial Symposium of the International Eosinophil Society
Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases
Editorial Accompanying Blood Cover Story Features Promise Of Dexpramipexole In Eosinophil-Associated Diseases
NIAID Now: Repurposed Drug Shows Promise for Treating Rare Eosinophilic Diseases
Knopp Biosciences Announces Publication of Phase 2 Trial Results of Dexpramipexole in Hypereosinophilic Syndromes (HES) in Blood
American Society of Hematology: “Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes”
The Laryngoscope: “Dexpramipexole Depletes Blood and Tissue Eosinophils in Nasal Polyps With No Change in Polyp Size”
Knopp Biosciences and APFED Announce Partnership to Advance Awareness of Hypereosinophilic Syndromes